The multiple sclerosis severity score (MSSS) predicts disease severity over time

Journal of the Neurological Sciences

Volumn 278, Issue 1-2, 2009, Pages 66-70

  Pachner, Andrew R ^a   Steiner, Israel ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Disease modifying drugs; EDSS; MSSS; Multiple sclerosis; Prognosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; METHYLPREDNISOLONE SODIUM SUCCINATE;

ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FUNCTIONAL DISEASE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCORE; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; UNITED STATES;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 58949099212     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.11.020     Document Type: Article

References (7)

1. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144-1151
2. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald" Criteria. Ann Neurol 58 (2005) 840-846
3. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
4. Weiner H.L., Mackin G.A., Orav E.J., Hafler D.A., Dawson D.M., LaPierre Y., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43 (1993) 910-918
5. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
6. Secondary Progressive Efficacy Clinical Trial Of Recombinant Interferon-Beta-1a in Multiple Sclerosis Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 (2001) 1496-1504
7. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Kooijmans M.F., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687